NASDAQ · Biotechnology · USD

Conexeu Sciences Inc. (CNXU) Stock Analysis

Conexeu Sciences Inc. (CNXU) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CNXU

$4.97

−$0.30 (−5.69%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CNXU with… →

CNXU Key Statistics

As of Sep 4, 2026

Trading

Open: $5.26
Previous Close: $5.27
Day's Range: 4.85–5.58
52-Week Range: 4.86–18.79
Volume: 249.50K

Valuation

Market Cap: $132.99M
P/E Ratio: unprofitable
EPS (ttm): −0.34

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$3.92M
Profit margin: 0.00%
Shares Outstanding: 26.76M

Dividend and dates

Avg Volume: 160.20K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CNXU Revenue and Earnings by Fiscal Year

FY ends October

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$3.92M	—
2024	$0.00	−$471.87K	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$3.96M	−$3.92M	—
2024	$0.00	—	−$643.04K	−$471.87K	—

Annual figures as reported, in the company's reporting currency. As of October 31, 2025.

CNXU Valuation vs Biotechnology Median

Median of 656 stocks

Metric	CNXU	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Conexeu Sciences Inc. (CNXU) is capitalised at $132.99M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry.

The most recent close on file for CNXU is $4.97, dated September 4, 2026. That is −$0.30 (−5.69%) against the previous close. Over the past 52 weeks the price has ranged from $4.86 to $18.79. The latest close sits 2.37% above that 52-week low.

Financial Health

In fiscal 2025, Conexeu Sciences Inc. reported revenue of $0.00. The same year closed with a net loss of $3.92M. The reported profit margin is 0%. Trailing earnings per share are −0.34.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Growth & Income

The record shows no dividend for CNXU.

So far in 2026 the price is −61.97%.

Peer Comparison

Conexeu Sciences Inc. (CNXU) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Conexeu Sciences Inc.	CNXU	$132.99M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Conexeu Sciences Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Conexeu Sciences Inc.

Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, breast, and butt volume restoration. Its CXU collagen gel is an investigational product targeting therapeutic and aesthetic indications, supporting tissue regeneration and aiming to minimize inflammation or fibrosis. The company's solutions are supported by preclinical and peer-reviewed data and are positioned as alternatives to conventional fillers or implants, with products currently investigational and pending regulatory clearance for certain applications. The company serves clients in the beauty, aesthetics, regenerative medicine, and medical sectors, including clinicians and professionals involved in facial rejuvenation, body contouring, wound care, and tissue repair. The company was founded in 2022 and is based in Reno, Nevada.

Visit website →